Karydas Daphne

Mineralys Therapeutics, Inc. · Director

Karydas Daphne is listed in filings as Director at Mineralys Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 17, 2026, including sale activity. Recent filings connect the profile to Mineralys Therapeutics, Inc. (MLYS) and COMPASS Pathways plc (CMPS). The current snapshot covers public activity from Feb 24, 2025 to Jun 17, 2026. Reported amounts are shown as $75.0K to $335.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.

Latest Trades

CompanyValueActionPriceLast Price
Mineralys Therapeutics, Inc.MLYS$75k3k sharesSellJun 17, 2026$25.00$26.71
Karydas Daphne insider trades and Form 4 filings | TradingNote